ID   NALL-1
AC   CVCL_3039
SY   Null-cell Acute Lymphoblastic Leukemia-1
DR   BTO; BTO:0004951
DR   ChEMBL-Cells; CHEMBL3307425
DR   ChEMBL-Targets; CHEMBL614769
DR   Cosmic; 801717
DR   Cosmic; 932760
DR   Cosmic; 998694
DR   Cosmic; 1037720
DR   GEO; GSM5137732
DR   GEO; GSM5137763
DR   JCRB; JCRB1332
DR   PRIDE; PXD023662
DR   PubChem_Cell_line; CVCL_3039
DR   Wikidata; Q54907390
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=155647;
RX   PubMed=197412;
RX   PubMed=200333;
RX   PubMed=2985879;
RX   PubMed=3159941;
RX   PubMed=3874327;
RX   PubMed=6097530;
RX   PubMed=8957066;
RX   PubMed=9680106;
RX   PubMed=9738977;
RX   PubMed=10739008;
RX   PubMed=11226526;
RX   PubMed=11986953;
RX   PubMed=35354797;
CC   Population: Japanese.
CC   Doubling time: 88 hours (Note=In RPMI 1640 + 20% HCS), 72 hours (Note=In RPMI 1640 + 20% FCS) (PubMed=200333).
CC   Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526).
CC   Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 8619; PAX5; Name(s)=PAX5-ETV6 (PubMed=35354797).
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): COG; JCRB=JCRB1332
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11,12
ST   D16S539: 11,13
ST   D18S51: 16,19
ST   D19S433: 13,14.2
ST   D21S11: 30,32.2
ST   D2S1338: 17,19
ST   D3S1358: 16
ST   D5S818: 10,12
ST   D7S820: 12,13
ST   D8S1179: 12,13
ST   FGA: 19,23
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C3168; Childhood acute lymphoblastic leukemia
DI   ORDO; Orphanet_513; Acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   14Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 23
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=155647;
RA   Han T., Minowada J.;
RT   "Use of stimulating capacity of mixed lymphocyte reaction (MLR-S) as a
RT   possible marker for the cell-origin of null-cell acute lymphoblastic
RT   leukaemia.";
RL   Immunology 35:333-339(1978).
//
RX   PubMed=197412; DOI=10.1038/267843a0;
RA   Miyoshi I., Hiraki S., Tsubota T., Kubonishi I., Matsuda Y.,
RA   Nakayama T., Kishimoto H., Kimura I., Masuji H.;
RT   "Human B cell, T cell and null cell leukaemic cell lines derived from
RT   acute lymphoblastic leukaemias.";
RL   Nature 267:843-844(1977).
//
RX   PubMed=200333; DOI=10.1002/1097-0142(197711)40:5<2131::AID-CNCR2820400523>3.0.CO;2-V;
RA   Hiraki S., Miyoshi I., Kubonishi I., Matsuda Y., Nakayama T.,
RA   Kishimoto H., Masuji H.;
RT   "Human leukemic 'null' cell line (NALL-1).";
RL   Cancer 40:2131-2135(1977).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//
RX   PubMed=6097530; DOI=10.1007/BF02619636;
RA   Yourno J., Samsonoff W.A., Willey A., Burkhart P., Lizzi F.,
RA   Tartaglia A.;
RT   "NALL-1, an acute lymphoblastic leukemia cell line with peroxidase
RT   activity.";
RL   In Vitro 20:884-888(1984).
//
RX   PubMed=8957066; DOI=10.1111/j.1349-7006.1996.tb03112.x;
RA   Kawasaki N., Matsuo Y., Yoshino T., Yanai H., Oka T., Teramoto N.,
RA   Liu C., Kondo E., Minowada J., Akagi T.;
RT   "Metastatic potential of lymphoma/leukemia cell lines in SCID mice is
RT   closely related to expression of CD44.";
RL   Jpn. J. Cancer Res. 87:1070-1077(1996).
//
RX   PubMed=9680106; DOI=10.1016/S0145-2126(98)00050-2;
RA   Matsuo Y., Drexler H.G.;
RT   "Establishment and characterization of human B cell precursor-leukemia
RT   cell lines.";
RL   Leuk. Res. 22:567-579(1998).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000),255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=11986953; DOI=10.1038/sj.leu.2402485;
RA   O'Donnell P.H., Guo W.-X., Reynolds C.P., Maurer B.J.;
RT   "N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to
RT   acute lymphoblastic leukemia cell lines, but not to non-malignant
RT   lymphocytes.";
RL   Leukemia 16:902-910(2002).
//
RX   PubMed=35354797; DOI=10.1038/s41467-022-29224-5;
RA   Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T.,
RA   Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E.,
RA   Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I.,
RA   Lehtio J., Vesterlund M., Jafari R.;
RT   "Integrative multi-omics and drug response profiling of childhood
RT   acute lymphoblastic leukemia cell lines.";
RL   Nat. Commun. 13:1691.1-1691.19(2022).
//